2920-86-7

Basic information

• Product Name: Prednisolone succinate
• Synonyms: PREDNISOLONE 21-HEMISUCCINATE;PREDNISOLONE HEMISUCCINATE;PREDNISOLONE SUCCINATE;4-diene-3,20-dione,21-(3-carboxy-1-oxopropoxy)-11,17-dihydroxy-pregna-(1;prednisolonbisuccinat;prednisolone21-succinate;prednisolonebisuccinate;prednisolut
• CAS NO: 2920-86-7
• Molecular Formula: C₂₅H₃₂O₈
• Molecular Weight: 460.52
• EINECS: 220-861-8
• Product Categories: RISPERDAL
• Mol File: 2920-86-7.mol
• Article Data: 7

Chemical Properties

• Melting Point: 206°C
• Boiling Point: 485.35°C (rough estimate)
• Flash Point: 233.528 °C
• Appearance: /
• Density: 1.1796 (rough estimate)
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.4480 (estimate)
• Storage Temp.: Refrigerator
• Solubility: DMSO (Slightly), Ethanol (Slightly), Methanol (Slightly)
• PKA: 4.29±0.17(Predicted)
• CAS DataBase Reference: Prednisolone succinate(CAS DataBase Reference)
• NIST Chemistry Reference: Prednisolone succinate(2920-86-7)
• EPA Substance Registry System: Prednisolone succinate(2920-86-7)

Safety Data

• Statements: 61-40
• Safety Statements: 53-22-36/37/39-45
• WGK Germany: 3
• RTECS: TU4153400
• Hazardous Substances Data: 2920-86-7(Hazardous Substances Data)

Usage

Uses

Prednisolone hemisuccinate, is a metabolite of Prednisolone (P703740), which is a synthetic glucocorticoid, a derivative of cortisol, and can be used to treat a variety of inflammatory and auto-immune conditions. It is also the active metabolite of the drug prednisone.

InChI:InChI=1/C25H32O8/c1-23-9-7-15(26)11-14(23)3-4-16-17-8-10-25(32,24(17,2)12-18(27)22(16)23)19(28)13-33-21(31)6-5-20(29)30/h7,9,11,16-18,22,27,32H,3-6,8,10,12-13H2,1-2H3,(H,29,30)/t16?,17?,18-,22?,23-,24-,25-/m0/s1

Upstream product

• 108-30-5 succinic acid anhydride 
• 50-24-8 prednisolon 
• 570370-45-5 (5-nitrothien-2-yl)methyl prednisolone-21-yl butanedioate 

Downstream Products

• 758722-59-7 prednisolone-21-O-β-carbonylpropionic acid p-nitrophenolic ester 
• 50-24-8 prednisolon 
• 110-15-6 succinic acid 

Relevant articles and documents

Prednisolone artificial antigen and preparation method and application thereof

The invention discloses a prednisolone artificial antigen and a preparation method and an application thereof. The prednisolone artificial antigen provided by the invention is an antigen obtained by coupling a prednisolone hapten represented by the formula I with a vector protein. The prednisolone artificial antigen provided by the invention has the advantages of simple synthetic method, high purity and high yield, and has significant value to preparation of a prednisolone antibody and detection of prednisolone drug residues.

Prednisolone-α-cyclodextrin-star PEG polypseudorotaxanes with controlled drug delivery properties

The reaction of α-amino-ω-methoxypoly(ethylene glycol) [M = 5000] or star α-amino-poly(ethylene glycol) [M = 20000] with hemiesters of prednisolone dicarboxylic acids (succinic, glutaric, adipic, phthalic acid) has been used to prepare the corresponding conjugates. The rate of esterase catalyzed hydrolysis of the conjugates is controlled by the molecular mass of poly(ethylene glycol) and the length of the linker between prednisolone and poly(ethylene glycol) (τ1/2 ～ 5-0.5 h). The enzymatic hydrolysis proceeds most rapidly at conjugates with linkers derived from adipic and phthalic acids. The synthesized conjugates form polypseudorotaxanes with α-cyclodextrin which were characterized by 2D NOESY NMR spectra, powder X-ray diffraction patterns and in one case also by STM microscopy. In the case of the polypseudorotaxane having the linker derived from adipic acid, the enzymatic release proceeds ca. five times slower in comparison with the rate of prednisolone release from the corresponding conjugate. The rate of prednisolone release from the carrier can be controlled by three factors: character of the linker between the polymeric carrier and prednisolone, the molecular mass of poly(ethylene glycol) and complex formation with α-cyclodextrin. The synthesized polypseudorotaxanes represent new promising transport systems intended for targeted release of prednisolone in transplanted liver.

Studies on the reductively triggered release of heterocyclic and steroid drugs from 5-nitrothien-2-ylmethyl prodrugs

Hypoxia (inadequate concentrations of dioxygen in tissues) is present in several disease states, including cancer and rheumatoid arthritis. Prodrug systems, which after bioreduction, selectively release active drugs in these tissues may be important in therapy. The 5-nitrothien-2-ylmethyl ester of aspirin was synthesised by treatment of 5-nitrothiophene-2-methanol with 2-acetoxybenzoyl chloride, whereas that of prednisolone hemisuccinate was prepared by reaction of prednisolone with 5-nitrothien-2-ylmethyl pentafluorophenyl butanedioate. In chemical model systems, both of these ester-linked potential prodrugs suffered hydrolysis, rather than reductively triggered release of the corresponding drug. 1-(5-Nitrothien-2-ylmethoxy)isoquinolines released the corresponding isoquinolin-1-ones (potent inhibitors of poly(ADP-ribose)polymerase) rapidly upon reduction of the nitro group with sodium borohydride/palladium, showing that these may be useful as reductively triggered prodrugs. In approaches to N-linked potential prodrugs, isoquinolin-1-one and nifedipine (a 1,4-dihydropyridine Ca2+ channel antagonist) were alkylated at nitrogen by 2-chloromethylthiophene but the corresponding 5-nitrothien-2-ylmethyl derivatives were synthetically inaccessible.